Intellia Therapeutics, a gene editing company, focuses on Crispr/Cas9-based therapeutics. Crispr/Cas9 technology is pivotal for precisely altering genomic DNA sequences to treat genetically defined diseases like ATTR amyloidosis and sickle cell disease. By utilizing in vivo and ex vivo therapies, Intellia aims to address diseases with high unmet medical needs. Collaborations with companies like Regeneron […]